Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1967 1
1977 3
1978 1
1979 1
1980 4
1981 3
1982 2
1983 1
1984 2
1985 3
1986 3
1987 6
1988 1
1989 4
1990 2
1991 2
1992 9
1993 9
1994 9
1995 8
1996 7
1997 5
1998 2
1999 2
2000 2
2001 3
2002 3
2003 8
2004 4
2005 5
2006 8
2007 3
2008 5
2009 2
2010 6
2011 8
2012 12
2013 17
2014 15
2015 16
2016 13
2017 7
2018 6
2019 8
2020 7
2021 6
2022 6
2023 10
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

257 results

Results by year

Filters applied: . Clear all
Page 1
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators. Younossi ZM, et al. Lancet. 2019 Dec 14;394(10215):2184-2196. doi: 10.1016/S0140-6736(19)33041-7. Epub 2019 Dec 5. Lancet. 2019. PMID: 31813633 Free article. Clinical Trial.
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Hirschfield GM, Shiffman ML, Gulamhusein A, Kowdley KV, Vierling JM, Levy C, Kremer AE, Zigmond E, Andreone P, Gordon SC, Bowlus CL, Lawitz EJ, Aspinall RJ, Pratt DS, Raikhelson K, Gonzalez-Huezo MS, Heneghan MA, Jeong SH, Ladrón de Guevara AL, Mayo MJ, Dalekos GN, Drenth JPH, Janczewska E, Leggett BA, Nevens F, Vargas V, Zuckerman E, Corpechot C, Fassio E, Hinrichsen H, Invernizzi P, Trivedi PJ, Forman L, Jones DEJ, Ryder SD, Swain MG, Steinberg A, Boudes PF, Choi YJ, McWherter CA; ENHANCE Study Group*. Hirschfield GM, et al. Hepatology. 2023 Aug 1;78(2):397-415. doi: 10.1097/HEP.0000000000000395. Epub 2023 Apr 6. Hepatology. 2023. PMID: 37386786 Free PMC article. Clinical Trial.
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.
Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C; CHEST-1 Study Group. Ghofrani HA, et al. N Engl J Med. 2013 Jul 25;369(4):319-29. doi: 10.1056/NEJMoa1209657. N Engl J Med. 2013. PMID: 23883377 Free article. Clinical Trial.
Surgery for primary hyperparathyroidism.
das Neves MC, Santos RO, Ohe MN. das Neves MC, et al. Among authors: ohe mn. Arch Endocrinol Metab. 2022 Nov 11;66(5):678-688. doi: 10.20945/2359-3997000000557. Arch Endocrinol Metab. 2022. PMID: 36382757 Free PMC article. Review.
Multidrug treatment for COVID-19.
Ohe M, Furuya K, Goudarzi H. Ohe M, et al. Drug Discov Ther. 2021 Mar 10;15(1):39-41. doi: 10.5582/ddt.2021.01005. Epub 2021 Feb 19. Drug Discov Ther. 2021. PMID: 33612572 Free article.
[Parathyroid carcinoma].
Vieira JG, Ohe MN, Hauache OM, Oliveira UM, Delana JM, Gonçalves A, Lazaretti-Castro M. Vieira JG, et al. Among authors: ohe mn. Arq Bras Endocrinol Metabol. 2005 Oct;49(5):811-5. doi: 10.1590/s0004-27302005000500023. Epub 2006 Jan 23. Arq Bras Endocrinol Metabol. 2005. PMID: 16444365 Free article. Review. Portuguese.
Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO).
Silva BC, Madeira M, d'Alva CB, Maeda SS, de Holanda NCP, Ohe MN, Szejnfeld V, Zerbini CAF, de Paula FJA, Bandeira F. Silva BC, et al. Among authors: ohe mn. Arch Endocrinol Metab. 2022 Nov 11;66(5):591-603. doi: 10.20945/2359-3997000000522. Epub 2022 Oct 3. Arch Endocrinol Metab. 2022. PMID: 36191263 Free PMC article.
257 results